Anthranilic acid amides: A novel class of antiangiogenic VEGF receptor kinase inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 26, 2002, Pages 5687-5693

  Manley, Paul W ^a   Furet, Pascal ^a   Bold, Guido ^a   Brüggen, Josef ^a   Mestan, Jürgen ^a   Meyer, Thomas ^a   Schnell, Christian R ^a   Wood, Jeanette ^a   Haberey, Martin ^b   Huth, Andreas ^b   Krüger, Martin ^b   Menrad, Andreas ^b   Ottow, Eckhard ^b   Seidelmann, Dieter ^b   Siemeister, Gerhard ^b   Thierauch, Karl Heinz ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 PYRIDYL)METHYL]AMINO N [3 (TRIFLUOROMETHYL)PHENYL]BENZAMIDE; 2 AMINOBENZAMIDE; ANTHRANILIC ACID DERIVATIVE; N 3 ISOQUINOLINYL 2 [(4 PYRIDINYLMETHYL)AMINO]BENZAMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG PENETRATION; ENZYME ANALYSIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

ADMINISTRATION, ORAL; AMIDES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTHRANILIC ACIDS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHO CELLS; CRICETINAE; ENZYME INHIBITORS; FEMALE; HUMANS; ISOQUINOLINES; LYMPHATIC METASTASIS; MELANOMA; MICE; PHOSPHORYLATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0037137612     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020899q     Document Type: Article

References (22)

1. Kerbel, R. S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000, 21, 505-515.
2. McDonnell, C. O.; Hill, A. D.; McNamara, D. A.; Walsh, T. N.; Bouchier-Hayes, D. J. Tumour micrometastases: The influence of angiogenesis. Eur. J. Surgical Oncol. 2000, 26, 105-115.
3. Neufeld, G.; Cohen, T.; Gengrinovich, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
4. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60, 203-212.
5. Makinen, T.; Jussila, L.; Veikkola, T.; Karpanen, T.; Keitunen, M. I.; Pulkkanen, K. J.; Kauppinen, R.; Jackson, D. G.; Kubo, H.; Nishikawa, S.-I.; Yla-Herttuala, S.; Alitalo, K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 2001, 7, 199-205.
6. Cochran, A. G. Antagonists of protein-protein interactions. Chem. Biol. 2000, 7, R85-R94.
7. Manley, P. W.; Furet, P. Prospects for anti-angiogenic therapies based upon VEGF inhibition. In Anticancer Agents: Frontiers in Cancer Chemotherapy; Ojima, I., Vite, G., Altmann, K., Eds.; ACS Symposium Series 796; American Chemical Society: Washington, DC, 2001; pp 282-298.
8. Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
9. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L.; Graham, G. A.; Hughes, G. D.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655.
10. Bold, G.; Altmann, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brueggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Roesel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Laesser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
11. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.-H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marme, D. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
12. Joachim, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Muller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.; Marme, D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000, 60, 4819-4824.
13. Mendel, D. B.; Laird, A. D.; Smolich, B. D.; Blake, R. A.; Liang, C.; Hannah, A. L.; Shaheen, R. M.; Ellis, L. M.; Weitman, S.; Shawver, L. K.; Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Des. 2000, 15, 29-41.
14. Levin, I. J.; Turos, E.; Weinreb, S. M. An alternative procedure for the aluminium-mediated conversion of esters to amides. Synth. Commun. 1982, 12, 989-993.
15. a determinations were carried out in parallel by potentiometric titration in water-KC (0.15 M) with 1,4-dioxan as cosolvent.
16. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
17. Hart, I. R.; Fidler, I. J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 1980, 40, 2281-2287.
18. SU5416 is not orally bioavailable and must be administered either by intraperitoneal or intravenous injection. Consequently, the compound was administered in the implant model by once-daily intraperitoneal injection. The compound was not evaluated in the mouse melanoma model.
19. Wood, J. M.; Schnell, C. R.; Brecht, K.; Walker, M.; Grossenbacher, R.; Fuerst, P.; Bold, G.; Ferrari, S.; Manley, P. W. Correlation between inhibition of bFGF-induced angiogenesis in an in vivo growth factor implant model and inhibition of tumor growth in tumors exhibiting different upregulation of bFGF for a series of selective VEGF receptor kinase inhibitors. Proc. Am. Assoc. Cancer Res. 2001, 41, 3127.
20. Manley, P. W.; Blum, W.; Bold, G.; Bruggen, J.; Hofmann, F.; Martiny-Baron, G.; Wood, J. M. NVP-AAD777/ZK202664, a selective VEGF receptor kinase inhibitor, which inhibits both VEGF- and bFGF-induced angiogenesis. Proc. Am. Assoc. Cancer Res 2001, 41, 4470.
21. Potgens, A. J.; van Altena, M. C.; Lubsen, N. H.; Ruiter, D. J.; de Waal, R. M. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am. J. Pathol. 1996, 148, 1203-1217.
22. Graeven, U.; Rodeck, U.; Karpinski, S.; Jost, M.; Philippou, S.; Schmiegel, W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res. 2001, 61, 7282-7290.